A randomized controlled multicentre open-label parallel arm study to assess the non-inferiority of the safety of bevacizumab compared to ranibizumab (allocation 4:1) administered by intravitreal injection in patients with macular degeneration or other exudative not age-related macular.
Phase of Trial: Phase IV
Latest Information Update: 18 Mar 2015
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab
- Indications Age-related macular degeneration; Choroidal neovascularisation; Diabetic macular oedema
- Focus Adverse reactions
- 18 Mar 2015 New trial record